Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine

Neurosci Lett. 1996 Oct 18;217(2-3):177-8.

Abstract

Clozapine is an atypical antipsychotic with affinity for a broad range of receptors, including serotonin (5-HT) and dopamine receptors. It is successful in treating about 60% of patients refractory to other antipsychotic drugs. Since genetic variation in clozapine's neurotransmitter receptor targets may affect clinical response through altering drug binding or receptor expression, we have studied a His452Tyr polymorphism in the 5-HT2A receptor (HTR2A) in a sample of 153 schizophrenic patients undergoing clozapine treatment and 178 normal controls. An association was found between the allele Tyr452 and poor clinical response.

Publication types

  • Clinical Trial

MeSH terms

  • Alleles
  • Antipsychotic Agents / pharmacology*
  • Antipsychotic Agents / therapeutic use
  • Clozapine / pharmacology*
  • Clozapine / therapeutic use
  • DNA / analysis
  • Genotype
  • Humans
  • Polymerase Chain Reaction
  • Polymorphism, Genetic
  • Psychiatric Status Rating Scales
  • Receptors, Serotonin / genetics*
  • Schizophrenia / drug therapy*
  • Schizophrenia / genetics*

Substances

  • Antipsychotic Agents
  • Receptors, Serotonin
  • DNA
  • Clozapine